Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
$2.90
+6.2%
$3.00
$1.72
$3.84
$27.21M1.6123,020 shs10,826 shs
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
$56.00
$55.66
$17.15
$56.48
$1.14B2.34301,073 shsN/A
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
C$1.44
-1.4%
C$1.51
C$1.20
C$4.49
C$108.61M1.4968,462 shs21,860 shs
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
+5.90%+6.25%-2.36%-15.00%-10.34%
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
0.00%0.00%0.00%0.00%+76.82%
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
-1.37%-5.88%-10.00%+5.11%-36.84%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
2.1897 of 5 stars
3.53.00.00.02.00.81.3
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
N/AN/AN/AN/AN/AN/AN/AN/A
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
0.4283 of 5 stars
3.50.00.00.00.00.00.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
3.00
Buy$6.00107.25% Upside
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
2.00
HoldN/AN/A
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
3.00
BuyC$3.00108.33% Upside

Current Analyst Ratings

Latest OBD, CIR, ACST, and ONC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/4/2024
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperformC$3.00
(Data available from 6/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/AN/AN/AN/A$9.14 per shareN/A
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
$786.92M1.45$4.77 per share11.74$7.81 per share7.17
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
N/AN/AC$0.34 per share4.22C$0.31 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
-$42.43M-$5.08N/AN/AN/AN/A-13.18%-11.32%6/28/2024 (Estimated)
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
$19.39M$1.3740.8819.51N/A3.40%35.32%5.21%N/A
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
-C$28.21M-C$0.40N/AN/AN/A-115.80%-63.83%8/12/2024 (Estimated)

Latest OBD, CIR, ACST, and ONC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024Q1 2024
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
-C$0.12-C$0.09+C$0.03-C$0.09N/AN/A
3/7/2024Q4 2023
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
-C$0.15-C$0.05+C$0.10-C$0.05N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/AN/AN/AN/AN/A
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
N/AN/AN/AN/AN/A
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/A
15.19
15.19
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
3.34
2.29
1.46
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
4.91
8.14
8.86

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
6.08%
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
96.16%
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
1.92%

Insider Ownership

CompanyInsider Ownership
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
13.51%
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
1.00%
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
3.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
329.40 million8.13 millionNot Optionable
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
3,06020.39 million20.19 millionOptionable
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
2975.42 millionN/ANot Optionable

OBD, CIR, ACST, and ONC Headlines

Recent News About These Companies

Stocks in play: Oncolytics Biotech Inc.
Outrun Therapeutics announces launch with $10m seed funding
Stocks in play: Oncolytics Biotech® Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acasti Pharma logo

Acasti Pharma

NASDAQ:ACST
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
CIRCOR International logo

CIRCOR International

NYSE:CIR
CIRCOR International, Inc. designs, manufactures, and distributes flow and motion control products in Europe, the Middle East, Africa, North America, and internationally. The company has a product portfolio of brands serving its customers' demanding applications. It operates through two segments, Aerospace & Defense and Industrial. The Aerospace & Defense segment manufactures and markets control valves, pumps, regulators, fluid controls, pneumatic valves and controls, electro-mechanical controls, electric motors, and other flow control products and subsystems; propeller pumps; actuation systems; MIL-spec butterfly valves and actuators; brushless DC motors; switches; and actuation components and sub-systems. Its products and services are used in the military and defense, commercial aerospace, business and general aviation, and general industrial markets, as well as serves aircraft manufacturers and tier 1 and tier 2 suppliers. This segment offers its products under the CIRCOR Aerospace, Aerodyne Controls, CIRCOR Bodet, CIRCOR Industria, CIRCOR Motors, Hale Hamilton, Leslie Controls, Portland Valve, and Warren Pumps brands. The Industrial segment provides 3 and 2 screw pumps, progressing cavity pumps, specialty centrifugal pumps, and gear metering pumps; automatic recirculation valves; engineered valves; positive displacement pumps; general service control valves; and top and bottom unheading devices and center feed devices for the end-users and original equipment manufacturers, as well as engineering, procurement, and construction companies. This segment offers its products under the Allweiler, DeltaValve, Houttuin, IMO Pump, IMO AB, Leslie Controls, RG Lawrence, RTK, Schroedahl, TapcoEnpro, Tushaco, and Zenith brands. The company markets its solutions directly and through various sales partners to approximately 14,000 customers in approximately 100 countries. CIRCOR International, Inc. was incorporated in 1999 and is headquartered in Burlington, Massachusetts.
Oncolytics Biotech logo

Oncolytics Biotech

TSE:ONC
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.